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ABSTRACT 
 
 
 
Pfiester, Pearl C. M.S., Purdue University, August 2012.  Strategies to Characterize 
Functional Regions of the Varicella-Zoster Virus Encapsidation Proteins.  Major 
Professor:  Robert J. Visalli. 
 
 
 
Varicella-zoster virus (VZV) is a double-stranded DNA virus that causes a self-
limiting primary infection known as chickenpox and can manifest into a painful, 
debilitating disease known as shingles in its latent form.  Current therapies target the 
DNA replication process, but novel studies propose targeting the encapsidation process of 
VZV.  The encapsidation process of VZV is based on the well-studied Herpes Simplex 1 
(HSV-1) homologs.  Seven genes or open reading frames (ORFs) are experimentally 
shown to be essential for HSV-1 DNA encapsidation.  This thesis explores two specific 
strategies to characterize functional regions of the VZV encapsidation proteins:  1) stable 
cell lines expressing putative VZV encapsidation proteins to grow VZV mutant viruses 
and 2) VZV ORF54 encapsidation protein transposon library development for use in 
functional studies.  It is hypothesized that specific regions of the encapsidation proteins 
will be essential for DNA packaging since it is known that any one deletion of HSV-1 
homologs results in accumulation of empty capsids and un-cleaved DNA in the nucleus 
of infected cells.   
Currently, VZV mutants lacking encapsidation genes do not exist.  It is expected 
that the deletion of each putative DNA encapsidation gene will yield a phenotype 
consistent with a defect in DNA cleavage and/or packaging.  Essential to developing 
VZV mutant viruses is the isolation of stable cell lines expressing the encapsidation 
protein.  The cell lines would complement the VZV mutant virus and can be used for 
further encapsidation studies.  Invitrogen’s Flp-In two-plasmid system was used to isolate 
	   xi 
isogenic cells lines from the encapsidation genes.  With the Flp-In system, stable cell 
lines expressing a protein of interest can be rapidly generated.  
The encapsidation protein known as the portal homolog, pORF54, could prove to 
be a novel target for antiviral therapy. Little is known about the role of specific functional 
regions within portal polypeptides including HSV-1.  Preparing an ORF54 transposon 
library for use in functional studies could be used for characterization of functional 
regions within the VZV portal protein.  It is expected that specific regions of pORF54 
will be essential for DNA encapsidation.  Briefly, ORF54 with flanking regions was 
isolated from the VZV genome of Ellen strain by PCR.  This fragment was inserted into 
Invitrogen’s Zero Blunt TOPO PCR cloning vector, and transformed into E. coli.  The 
Epicentre EZ-Tn5 In-Frame Linker Insertion Kit was used to prepare in frame insertions 
of the 19 amino acid transposon throughout the ORF54 plasmid for mutagenesis.  
Characterization of wild type ORF54 and mutated ORF54 can be accomplished by 
complementation with a null ORF54 bacterial artificial chromosome (BAC) via 
transfection (Roche’s FuGene6) into human retina cells (ARPE-19).  The importance of 
ORF54 regions will be determined by complementing the ORF54 null virus with the 
mutated ORF54 gene.  It is hypothesized that specific regions of pORF54 will be 
essential since it is known that deletion of the HSV-1 portal protein homolog is lethal.  
This will be the first comprehensive study to characterize potential important function 
regions within any large DNA virus portal protein. 
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INTRODUCTION 
 
 
 
 There are three main groups of herpesvirus:  alpha (α), beta (β), and gamma (γ).  
They are based on genetic similarity, host range, replication cycle, and the cell type in 
which they establish latency (A. M. G. A. A. Arvin, 2000) (Figure 1).  The studies 
described in this thesis focus on Varicella-zoster virus (VZV), which is an 
alphaherpesvirus.   
 
 
 
 
 
 
 
 
 
 
Figure 1.  Proposed phylogenetic tree for mammalian herpesviruses  (A. M. G. A. A. 
Arvin, 2000).   
 
VZV is a linear double-stranded DNA virus with a genome of approximately 125 
Kbp.  Encoding 70 putative genes or ORFs (open reading frames), it has the smallest 
genome of the eight human herpesviruses (A. M. G. A. A. Arvin, 2000).  The genome is 
contained within an icosahedral capsid that is surrounded by a protein tegument layer.  
The outermost layer is a host cell-derived lipid envelope decorated with virus specific 
glycoproteins acquired during egress from the host cell (Carter, 2007). 
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 In general, alphaherpesviral replication includes attachment of the virus to a cell 
surface ligand followed by fusion of the viral envelope with the host cell membrane.  
Upon fusion, viral tegument proteins are released into the cytoplasm (Meckes & Wills, 
2007) while the capsid is quickly transported along microtubules towards the nucleus 
(Sodeik, Ebersold, & Helenius, 1997).  Some of the tegument proteins are used to down-
regulate host DNA, RNA, and protein synthesis.  Other tegument proteins are transported 
to the nucleus to activate viral gene expression (H. Moriuchi, Moriuchi, Straus, & Cohen, 
1993; M. Moriuchi, Moriuchi, Straus, & Cohen, 1994).  Once the capsid stabilizes on a 
nuclear pore, the linear DNA releases through the portal protein, the opening to the 
capsid (Ojala, Sodeik, Ebersold, Kutay, & Helenius, 2000; Sodeik et al., 1997).  The 
linear DNA becomes a covalently closed circle and associates with cell histones.   
 Herpesvirus genes are expressed in three phases:  immediate early (IE), early (E), 
and late (L).  Once the genome is in the host nucleus, tegument proteins act as 
transcription factors to activate IE genes and recruit host RNA polymerase.  These IE 
proteins become transcription factors that regulate expression for E and L genes.  E genes 
encode proteins important for viral replication.  The origin-binding protein binds to ori 
sites in the circular dsDNA and starts to unwind the replication forks.  The viral DNA 
polymerase replicates the genomic DNA by a rolling circle mechanism to produce 
multiple copies of viral genomic concatemers.  L genes typically encode structural 
proteins used to make empty immature procapsids and glycoproteins, as well as tegument 
proteins that will be packaged into the final virus particle.  Capsid proteins are 
synthesized in the cytoplasm then transported into the nucleus where they self-assemble 
into procapsids.  Scaffold proteins stabilize the procapsids until one viral genome is 
packaged inside the capsid.  Scaffold proteins are removed by a viral protease during 
genome packaging.  There are specific packaging signals that are recognized on the 
genome by a set of proteins known as encapsidation proteins.  These proteins cleave the 
concatemeric DNA and ensure that precisely one genome is packaged per capsid (Figure 
2).  Viral encapsidation enzymes, known as the terminase complex, cleave at packaging 
signals and transport the genome to enter the procapsid through the viral portal protein.  
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The DNA-filled capsid will then acquire tegument and envelope proteins upon egress 
through the Golgi complex and cell plasma membrane (Carter, 2007). 
 
 
Figure 2.  During rolling circle genome replication, concatemeric DNA is produced.   
Viral proteins cleave at packaging signals to ensure one genome is packaged per capsid 
(Carter, 2007). 
 
 VZV can continue the lytic cycle by infecting additional mucosal epithelial cells, 
or cause latency in the nervous system.  During the lytic cycle, VZV is a respiratory virus 
that initially infects the lungs and lymph nodes (Moffat, Ku, Zerboni, Sommer, & Arvin, 
2007).  Afterwards, it spreads via the bloodstream to the skin and infects mononuclear 
cells to cause the rash of varicella known as chickenpox (A. M. Arvin, Moffat, & 
Redman, 1996).  VZV can infect the dorsal root and cranial nerve ganglia to establish 
latency by limiting its expression of viral proteins for the lifetime of the host 
(Mahalingam et al., 1990; Mahalingam, Wellish, Dueland, Cohrs, & Gilden, 1992).  
Upon reactivation from latency, VZV causes herpes zoster or shingles at the epithelial 
surface.  Transmission to other humans can occur by direct contact of lesions or 
conjunctiva or breathing in infectious droplets (Cohen, Brunell, Straus, & Krause, 1999; 
Moffat et al., 2007). 
 Current drug therapies for VZV include nucleoside analogs such as acyclovir, 
valacyclovir, penciclovir, famciclovir, ganciclovir, and valganciclovir.  These prodrugs 
inhibit viral replication by targeting the viral DNA polymerase, the enzyme responsible 
for DNA elongation (Elion, 1983; Frank, Chiou, & Cheng, 1985).  When the nucleoside 
analog is incorporated into the viral DNA, DNA elongation is blocked because there is no 
free 3’ hydroxyl group.  Unfortunately, these prodrugs have poor bioavailability and toxic 
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side effects (Haynes, Lambert, & Mitchell, 1996; Tomicic, Bey, Wutzler, Thust, & 
Kaina, 2002).  Since these prodrugs have a similar target, resistance occurs in the viral 
phosphotransferase genes which are the enzymes responsible for phosphorylation of 
nucleosides (Elion, 1983).  Resistance to a drug can be avoided by inhibiting a new target 
like encapsidation instead of DNA elongation (Visalli & van Zeijl, 2003).    
 Encapsidation among the herpesviruses share similar methods of DNA 
translocation and packaging of the genome into an assembled icosahedral capsid.  There 
are seven essential herpesvirus encapsidation genes that are conserved throughout the 
herpesvirus family (Alba, Das, Orengo, & Kellam, 2001).  The virus-encoded multi-
protein complex that cleaves DNA concatemers into genome-lengths and packages them 
into procapsids is collectively known as the encapsidation machinery (Scheffczik, Savva, 
Holzenburg, Kolesnikova, & Bogner, 2002).  When any one of these genes was deleted 
from HSV-1, empty capsids and un-cleaved DNA accumulated in the nucleus (Beard, 
Taus, & Baines, 2002; Chang, Poon, & Roizman, 1996; Goshima et al., 2000; Koslowski 
et al., 1999; Lamberti & Weller, 1996, 1998; McNab et al., 1998; Newcomb, Homa, 
Thomsen, & Brown, 2001; Ogasawara, Suzutani, Yoshida, & Azuma, 2001; Patel & 
MacLean, 1995; Patel, Rixon, Cunningham, & Davison, 1996; Reynolds, Fan, & Baines, 
2000; Salmon & Baines, 1998; Sheaffer et al., 2001; Taus & Baines, 1998; Yu & Weller, 
1998).  VZV putative encapsidation homologs are ORF25, ORF26, ORF30, ORF34, 
OF43, ORF42/45, and ORF54 (Sheaffer et al., 2001).    
After concatemeric DNA is cut into genome-lengths, the portal protein serves to 
form the channel for DNA import into preformed capsids for herpesvirus encapsidation 
(Adelman, Salmon, & Baines, 2001; Holzenburg, Dittmer, & Bogner, 2009).  It has been 
shown that the terminase complex for herpesviruses translocates the DNA into the capsid, 
which is composed of the large and small subunit.  In human cytomegalovirus (HCMV), 
a virus from the betaherpesvirus family, the terminase complex consists of the large 
subunit, pUL56, and the small subunit, pUL89.  The large subunit has ATPase activity 
whereas the small subunit cleaves concatemeric DNA (Hwang & Bogner, 2002; 
Scheffczik et al., 2002). 
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In addition to the terminase complex, putative portal proteins are homo-
multimeric where monomers can self-assemble into multimers without viral proteins, 
occupy one vertex on the capsid, and bind to DNA and the terminase complex (Dittmer & 
Bogner, 2005; Holzenburg et al., 2009; Newcomb, Juhas, et al., 2001; Trus et al., 2004; 
Valpuesta & Carrascosa, 1994).  Even though portal proteins do not share sequence 
homology, the secondary structures of portals are similar.  Portal proteins have a crown, 
wing, and stalk shape (Dittmer & Bogner, 2005; Holzenburg et al., 2009; Trus et al., 
2004).  Structural studies with HSV-1 have shown that the wing and crown are oriented 
toward the capsid while the stalk is pointing away from the capsid (Trus et al., 2004).  
Based on amino acid sequence alignments, all herpesvirus portal homologs have 6 alpha 
helices and a putative leucine zipper motif in an alpha helix which is thought to be 
involved in DNA binding (Lebedev et al., 2007; Nellissery, Szczepaniak, Lamberti, & 
Weller, 2007; Newcomb, Homa, & Brown, 2005; Simpson et al., 2000).   
In HCMV, the portal protein, pUL104, directly interacts with pUL56 terminase 
(Dittmer, Drach, Townsend, Fischer, & Bogner, 2005)  since pUL104 and pUL56 
coimmunoprecipitated in GST pull down assays and were detected to co-localize during 
infection in immunofluorescence (IF) assays.  The interaction between pUL45 and 
pUL104 was blocked when benzimidazole-D-ribonucleoside was added.  This was 
detected by immunoprecipitating pUL56 from infected cell lysates then finding the 
presence of pUL104 by western blot (Dittmer et al., 2005).  Purified monomers of 
pUL104 can self-assemble into dimers and multimers by chemical cross-linking in non-
reducing conditions.  Recombinant pUL104 was purified by utilizing the baculovirus 
system and observed by electron micrograph.  The crown, wing, and stalk domains were 
in agreement (Holzenburg et al., 2009) with other portal proteins such as dsDNA 
bacteriophage phi29 and HSV-1 (Trus et al., 2004) (Figure 3).  It has been confirmed that 
the putative pUL104 occupies one vertex on the capsid by immunoelectron microscopy 
(Scheffczik et al., 2002).  Finally, it has been shown that pUL104 can bind to a dsDNA 
column (Dittmer & Bogner, 2005).   
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Figure 3.  Electron microscopy of HCMV portal protein, pUL104.  Different views of 
pUL104 (A-K), a diagram of pUL104 (l) compared to the model of bacteriophage Φ29 
portal (Holzenburg et al., 2009; Trus et al., 2004). 
 
In HSV-1, the portal protein, pUL6, occupies one vertex on the capsid by 
immunoelectron microscopy and forms ring-like structures after pUL6 purification from 
baculovirus expression (Newcomb et al., 2005; Newcomb, Juhas, et al., 2001; Patel & 
MacLean, 1995) (Figure 4).  Disulfide bonds between monomeric portal units is required 
for portal ring formation and stability for encapsidation (Albright, Nellissery, 
Szczepaniak, & Weller, 2011).  Based on electron microscopy and image analysis, UL6 
consists of 12 monomers to form a portal with a crown, wing, and stalk domain (Trus et 
al., 2004).    It has been shown that UL6 interacts with both terminase subunits pUL15 
and pUL28 by an immunoprecipitation assay and immunofluorescence (White, Stow, 
Patel, Hughes, & Preston, 2003; Yang, Wills, & Baines, 2009).  HSV-1 strains resistant 
to thiourea compound encapsidation inhibitors had three single amino acid mutations 
mapped to UL6, two close to the C terminus and one close to the N terminus (van Zeijl et 
al., 2000).   
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Figure 4.  Electron micrograph of HSV-1 capsids was used to identify the location of 
HSV portal protein, UL6.  UL6 was identified by primary UL6 specific antibody 
followed by gold-labeled secondary antibody (Newcomb et al., 2005).   
 
In addition, the portal protein, pUL6, binds to the scaffold protein, pUL26.5 
(Newcomb, Thomsen, Homa, & Brown, 2003).  This interaction has been confirmed by 
deletion mutants which identified a region of the scaffold protein required for portal 
protein interaction (Singer, Newcomb, Thomsen, Homa, & Brown, 2005).  It has been 
suggested that portal is incorporated early during capsid assembly since capsids without 
portal formed when portal was absent during early incubations (Newcomb et al., 2005).  
Since ORF54 shows 44% amino acid similarity to the HSV-1 portal protein 
homolog, it is reasonable to consider that ORF54 may have a similar role as UL6 (Visalli 
& van Zeijl, 2003).   VZV portal protein, pORF54, has recently been isolated and 
electron-microscopy showed that pORF54 exhibits a ring-like shape that could be similar 
to HSV-1 pUL6 and HCMV pUL104 homologs (Howard, Sherman, Visalli, Burnside, & 
Visalli, 2012) (Figure 5). 
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Figure 5.  Isolation of VZV portal protein, ORF54, by sucrose gradient density 
centrifugation from recombinant baculovirus extracts (Howard et al., 2012). 
 
Similar to HCMV pUL104 and HSV-1 pUL6 portal proteins, VZV pORF54 is 
also inhibited by thiourea compounds.  VZV strains resistant to thiourea compounds had 
their resistance mapped to ORF54.  When these thiourea compounds inhibited VZV Ellen 
wild type replication, only empty capsids were observed (Visalli et al., 2003).   
Little is known about the role of specific functional regions within the various 
encapsidation proteins of VZV.  The purpose of this thesis is to develop strategies to 
characterize important functional regions of the encapsidation proteins.  Two strategies 
will be used.  One will involve the development of stable cell lines expressing 
encapsidation proteins.  The second strategy will be the development of encapsidation 
protein transposon libraries for use in functional studies.  It is hypothesized that specific 
regions of encapsidation proteins will be essential for DNA encapsidation since it is 
known that deletion of any one of the HSV-1 homologs results in accumulation of 
immature capsids and infection (Patel et al., 1996).  
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CHAPTER 1 
 
 
STRATEGY 1:  CELL LINE COMPLEMENTATION AS A TOOL TO STUDY  
 
ENCAPSIDATION GENE MUTANTS 
 
 
 
Introduction 
Mutant viruses containing deletions in DNA encapsidation genes have been 
characterized for HCMV, HSV-1, and pseudorabies virus (PRV) (Beard et al., 2002; 
Borst, Wagner, Binz, Sodeik, & Messerle, 2008; Fuchs, Klupp, Granzow, Leege, & 
Mettenleiter, 2009).  However, similar mutants for VZV do not exist.  It is expected that 
the deletion of each putative DNA encapsidation gene will yield a phenotype consistent 
with a defect in DNA cleavage and/or packaging.  Complementing the deleted ORF in 
the VZV genome by cell lines expressing the respective DNA encapsidation proteins will 
produce VZV mutant viruses.  Essential to this process is the isolation of stable, DNA 
encapsidation protein expressing cell lines.  Previously, each encapsidation ORF was 
cloned into the mammalian expression vector, pcDNA3.1 D-V5-His-Topo.  Transient 
expression of each pORF (ORF25, ORF26, ORF30, ORF34, ORF45/42, ORF43, and 
ORF54) was confirmed in MeWo cells by indirect immunofluorescence microscopy 
using a V5 monoclonal antibody (Visalli et al., 2007).  Therefore, stable cell line 
expressing DNA encapsidation proteins were attempted using these vectors in MeWo 
cells.   
Based on the results of producing stable MeWo cell lines, the Flp-In two-plasmid 
system (Invitrogen) was used to isolate isogenic cell lines.   With the Flp-In system,  
stable cell lines expressing a protein of interest can be rapidly generated.  The Flp-In cells 
utilize an FRT site for targeted integration of the plasmid into the host cell line (CV-1) 
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genome.  A Flp-In expression vector is used to specifically target the FRT site to increase 
the possibility of isolating a stable isogenic cell line expressing a high level of the gene of 
interest.  The Flp-In vector and Flp recombinase vector, pOG44, require co-transfection 
into the Flp-In host cell line (CV-1).  Successful integration occurs when the hygromycin 
gene acquires the promoter and ATG codon from the lacZ-Zeocin gene.  Ideally, each 
isogenic cell line would be sensitive to zeocin, resistant to hygromycin, lacks β-
galactosidase activity, and constitutively expresses a high level of VZV ORF (Figure 6).  
After transfection, cell lines were tested for expression of the VZV ORF by indirect 
immunofluorescence microscopy, PCR, β-galactosidase assay, immunoblotting, 
immunoprecipitation followed by immunoblotting, and complementation of ΔORF VZV 
BAC (null virus without ORF). 
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Figure 6.  Schematic diagram of the Flp-In two-plasmid system (Invitrogen).  Host cell 
line has β-galactosidase activity and zeocin resistance.  When transfection is successful, 
the lacZ-Zeocin gene loses the promoter and ATG codon while the hygromycin B gains it 
(http://tools.invitrogen.com/content/sfs/manuals/flpinsystem_man.pdf).    
 
Methods 
 
Cells and Virus 
 Monolayer cultures of human melanoma (MeWo) or African green monkey 
kidney (CV-1) Flp-In cells (Invitrogen, Lot:  435779) were used for transfection and 
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propagation of VZV strain Ellen (ATCC VR-1367).  MeWo cells were grown in Minimal 
Essential Medium (MEM) supplemented with 8% fetal bovine serum (FBS), 2 mM L-
glutamine, 0.1 mM non-essential amino acids, 100 units/ml of penicillin, 100 mg/ml 
streptomycin sulfate and β-amphotericin.  CV-1 cells were grown in Dulbecco’s 
Modified Eagles Medium (DMEM) supplemented with 8% fetal calf serum, 2 mM L-
glutamine, 100 units/ml of penicillin, 100 mg/ml streptomycin sulfate, β-amphotericin, 
and 100 mg/ml of Zeocin.  Cells infected with VZV were incubated in either DMEM or 
MEM containing 3% serum.  Infections were performed with VZV-infected cell stocks 
applied to monolayers of uninfected cells.  Cells were maintained at 37°C in a CO2 
incubator.   
 For plaque assays, cells were infected with serially diluted VZV.  After 7 to 10 
days, cells were washed with phosphate buffered saline (PBS), incubated with 10% 
formalin for 1 hour, stained with crystal violet for 1 hour, and rinsed with water to count 
plaques. 
 
Strain Maintenance 
 E. coli transformed using pcDNA3.1 D-V5-His-Topo (Invitrogen) and an 
encapsidation gene, ORF25 (IPFW90), ORF26 (IPFW 64), ORF30 (IPFW 65), ORF43 
(IPFW 66), ORF45/42 (IPFW 68), ORF54 (IPFW 70), and ORF34 (IPFW 92), were  
grown in LB media with 100 µl/ml ampicillin at 37°C (Visalli et al., 2007).  Plasmid 
DNA was extracted and used for MeWo transfection.    
 E. coli transformed using pEF5/FRT/V5-D-TOPO (Invitrogen) and an 
encapsidation gene, ORF25 (IPFW150), ORF30 (IPFW157), ORF45/42, ORF42 
(IPFW153), ORF45 (IPFW155), ORF54 (IPFW154), ORF34, ORF26 (IPFW156), 
ORF43 (IPFW158), and pOG44 were grown in LB media and 100 µg/ml of ampicillin  at 
37°C.  Plasmid DNA was extracted and used for CV-1 transfection. 
 
DNA Extraction 
 Plasmid DNA was purified from E. coli cultures using either Zippy Plasmid 
Miniprep (Zymo) or Qiagen Miniprep kits.  A ND-1000 (NanoDrop) Spectrophotometer 
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was used to determine the quality and concentration of DNA.  Plasmid DNAs were stored 
at -20oC.  A Qiagen Midiprep kit was used to purify larger quantities of pOG44 from 
larger cultures (~100 ml). 
 The TissueDirect Multiplex PCR system (GenScript) was used to extract genomic 
DNA from cells in 6-wells.  Lysis buffer was prepared by mixing 2.5 µl of TD-A and 
22.5 µl of TD-B per well of a 6-well plate.  Cells were scraped into 200 µl of water and 
7.5 µl of cells was mixed into the lysis solution.  After incubation for 10 min at 65°C, 25 
µl of TD-C was added and the sample was centrifuged at 14,000 rpm for 1 minute.  2 µl 
of genomic DNA was used per PCR reaction.   
 The Blood and Cell Culture DNA Mini Kit (Qiagen) was used to extract and 
purify genomic DNA from cells.  Cells in TC-100 plates were harvested by scraping, 
washed with PBS, pelleted by centrifugation, and processed as per the manufacturer’s 
protocol.  DNA pellets were air-dried and resuspended in 100 µl of TE (pH 8.0) buffer at 
55°C for 1.5 hours, or overnight while gently shaking.   
 DNA concentration and purity was determined using a ND-1000 (NanoDrop) 
Spectrophotometer.  Each sample was further analyzed by agarose gel electrophoresis to 
confirm the presence of high molecular weight genomic DNA and plasmids.   
 
Transformation 
 Plasmid DNA was transformed into One Shot (Invitrogen) chemically competent 
E. coli cells by heat-shocking cells for 30 seconds in a 42°C water bath.  E. coli was 
diluted on to plates containing the appropriate antibiotic and incubated overnight at 37°C.  
After 24 hours, a colony was picked to grow in LB media containing the appropriate 
antibiotic.   
 
Geneticin Sensitivity Assay 
 MeWo cells were diluted in 60 mm plates at dilutions of 1:6, 1:12, and 1:24 from 
a confluent TC-100 plate.  Geneticin stock was prepared at 50 mg/ml in 100 mM HEPES, 
pH 7.3 buffer and filter sterilized.  Geneticin was tested at concentrations of 0, 31.25, 
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62.5, 125, 250, and 500 µg/ml in each TC-60 plate.  MeWos were re-fed every 3 to 4 
days for maintenance in the appropriate amount of geneticin.   
 
Transfection 
 MeWo cells were either mock-transfected or transfected with pcDNA3.1D/V5 
(Invitrogen) containing VZV ORFs.   
 CV-1 Flp-In cells were either mock-transfected or transfected with 
pEF5/FRT/V5-D-TOPO (Invitrogen) containing VZV ORFs and pOG44 at a ratio of 1:9 
respectively.   
 DNA and Lipofectamine 2000 were diluted separately in 250 µl of Opti-MEM 
serum free media and incubated for 5 minutes at room temperature.  Diluted DNA was 
mixed into diluted Lipofectamine 2000 and incubated for 20 minutes at room 
temperature.  Cell monolayers in 6-well cell culture plates were washed with PBS and the 
media was changed to Opti-MEM serum free media.  The diluted DNA/Lipofectamine 
complex was added to cells and incubated for 4 to 6 hours.  After incubation, the media 
was changed to media with 5% FBS.  After 24 hours, geneticin was added to MeWo cells 
or hygromycin B was added to CV-1 cells to select resistant clones.  Three to four days 
post-transfection, cells were examined by indirect immunofluorescence microscopy for 
protein expression, or they were serially diluted 1:2, 1:4, 1:8, 1:16, and 1:32 into 60 mm 
plates and maintained with geneticin or hygromycin B to select isolated, resistant clones.   
 Transient expression in either cell type was performed in the absence of the 
selection agent and pOG44 vector (CV-1). 
 
Polymerase Chain Reaction (PCR) 
 PCR was performed with high-fidelity Phusion polymerase.  Reactions included 
10.8 µl water, 4 µl 5X Phusion HF buffer, 0.4 µl 10mM dNTPs, 0.6 µl dimethylsulfoxide 
(DMSO), 0.2 µl Phusion DNA polymerase, 1 µl each forward and reverse primer, and 2 
µl template DNA.  The reaction conditions comprised initial denaturing at 98°C for 30 s, 
30 total cycles of denaturing at 98°C for 10 s, annealing at 52°C for 15 s, extension at 
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72°C for 15 s, and a final extension at 72°C for 5 minutes.  PCR products were analyzed 
on 0.8% agarose gels and visualized after staining with ethidium bromide (EtBr).   
 
β-galactosidase Assay 
 The β-gal Staining Kit (Invitrogen) was used to detect the expression of lacZ in 
transfected cells.  The substrate, X-gal, is hydrolyzed in the presence of β-galactosidase 
and results in a color change (blue staining).  The amount of staining was monitored 
every half hour and cells were rinsed with PBS and overlaid with 70% glycerol at 4°C 
when the reaction was complete.   
 
Indirect Immunofluorescence Microscopy 
 Method 1:  Cells grown on sterile glass cover slips were washed with PBS, fixed 
in a 50% methanol/50% ethanol solution for 2 min, washed with PBS, and blocked in 1% 
goat serum diluted in PBS for 1 hr.  1% goat serum in tris buffered saline containing 
tween (TBST) was used for washes and antibody dilutions.  Cells were incubated with α-
V5 monoclonal antibody (1:500) for 1 hr, washed, incubated with fluorescein 
isothiocyanate-conjugated (FITC) donkey α-mouse secondary antibody or Rhodamine 
red donkey α-mouse secondary antibody (1:200) for 45 minutes.  A 15 min incubation of 
a 1:10,000 dilution of 4′,6-diamidino-2-phenylindole (DAPI) was used as a general stain 
for cell nuclei.  Slides were mounted with 50% glycerol/50% PBS for examination by 
fluorescence microscopy. 
 Method 2:  Alternatively, glass cover slips were incubated for 24-48 hours with a 
mixture of uninfected and VZV strain Ellen infected cells.  Cover slips were fixed as 
described above and blocked in 3% bovine serum albumin (BSA) in TBST for 1 hour, 
washed with PBS, and incubated with a 1:300 dilution of either monoclonal mouse 
antibody specific for the VZV major capsid protein (Virusys Corp.), glycoprotein E (gE), 
or glycoprotein I (gI) at 1:300 for one hour.  Slides were washed with 1% Triton X-100 in 
PBS and incubated with a 1:200 dilution of fluorescein isothiocyanate-conjugated donkey 
anti-mouse secondary antibody for 30 minutes.  A 15 min incubation of a 1:10,000 
dilution of 4′,6-diamidino-2-phenylindole (DAPI) was used as a general stain for cell 
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nuclei.  Slides were mounted with 50% glycerol/50% PBS for examination by 
fluorescence microscopy. 
 
Immunoblotting 
 Proteins were detected by SDS-PAGE and immunoblot analysis.  Cells were 
washed twice with PBS and removed from plates with sample buffer (1 M Tris, 6.8 pH, 
glycerol, 20% sodium dodecyl sulfate, bromophenol blue).  β-mercaptoethanol was 
added to a final concentration of 5%.  Cells were sonicated (Sonifier 150 Ultrasonic Cell 
Disruptor) in ice, boiled for 5 min, and loaded onto 10% Tris gels.  Fractionated proteins 
were transferred to Immobilon transfer membrane (Millipore) overnight at 25 volts.  The 
blot was blocked in blotto/tween (TBST + milk) for 1 hr.  TBST was used for all blot 
washes and antibody dilutions.  Transfected cells containing the V5 epitope were 
detected with an α-V5 monoclonal mouse antibody (Serotec, Inc.) or α-V5 goat antibody 
(GenScript).  This was followed by a goat α-mouse or rabbit α-goat HRP-conjugated 
secondary antibody (Pierce), or alkaline phosphatase-conjugated goat α-mouse secondary 
antibody (Jackson ImmunoResearch).  Chemiluminescent detection with HRP conjugates 
was performed using the SuperSignal West Pico Chemiluminescent Substrate System 
(Pierce).  Western Blue Stabilized Substrate was used for detection of alkaline 
phosphatase conjugates.   
 
Immunoprecipitation  
 Method 1:  The Pierce Classic IP Kit (Thermo Scientific) was used to concentrate 
VZV pORFs containing the V5 epitope for subsequent immunoblotting.  Cells in 6-well 
culture plates were washed with cold PBS and resuspended in 400 µl of ice-cold IP 
Lysis/Wash buffer per well.  After incubation on ice for 20 minutes, cells were scraped 
off the plates and collected.  The lysates were clarified at 13,000 x g for 10 minutes at 
4°C.  The supernatants were applied to a spin column and 2 µl of anti-V5 polyclonal goat 
antibody was incubated for 1 hr at 4°C with constant rocking.  Then, 20 µl of 50% 
Protein A/G-Agarose beads were washed and centrifuged at 1,000 g for 1 minute.  The 
beads were added to the spin column for incubation overnight at 4°C.  The beads were 
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washed four times with 200 µl of lysis/wash buffer and washed once with 1X 
conditioning buffer.  Immune complexes were boiled in 20 µl of 5X sample buffer, 29 µl 
of water, and 1 µl of 1M DTT per cell lysate.  The immunoprecipitated material was 
centrifuged and collected for immunoblot analysis. 
 Method 2:  Alternatively, mock or transfected cells were washed with cold PBS 
and resuspended in 1 ml of cold RIPA buffer (NaCl, NP-40 alternative, deoxycholic acid, 
sodium dodecyl sufate, 1 M Tris, pH 7.5) per TC-100 plate.  After incubation on ice for 
30 minutes, cells were scraped and sonicated.  Lysates were either boiled for 10 minutes 
(to release potential DNA binding proteins) or left unboiled and clarified by centrifuging 
at 10,000 x g for 10 minutes at 4oC.  Precleared lysate was reacted with 2 µl of 
monoclonal anti-V5 mouse antibody and 50 µl of washed Protein G PLUS/Protein A-
agarose slurry overnight at 4oC with constant rocking.  The beads were pelleted by 
centrifugation at 10,000 X g for 1 minute and washed five times with cold RIPA buffer.  
Immune complexes were boiled in 20 µl of sample buffer containing 5% β-
mercaptoethanol for 10 minutes.  The immunoprecipitated material was centrifuged and 
collected for immunoblot analysis.   
 
Complementation of ΔORF VZV BAC 
 ΔORF54 and ΔORF30 VZV Bacterial Artificial Chromosome DNA (null virus 
without ORF54) was transformed into E. coli and was generously provided by Dr. Hua 
Zhu (Rutger’s University School of Medicine) (Zhang et al., 2010).  The VZV BAC 
DNA construct contains the hygromycin, chloramphenicol, and kanamycin resistant 
genes as well as the reporter GFP and luciferase.  ΔBAC DNA (0.2 µg/µl) and 
Lipofectamine (10 µl) complexes were transfected into the VZV ORF CV-1 Flp-In cell 
lines.  After 4 to 7 days, slides were incubated for 15 minutes with a 1:10,000 dilution of 
DAPI and then analyzed for plaque formation by GFP expression.   
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Results 
 
MeWo Cell Line 
 The VZV ORFs of greatest interest in our laboratory are ORF30 and ORF54.  
Stable cell line production was first attempted by transfecting the 3.1D-V5-His-Topo 
(Invitrogen) vector containing a full length VZV ORF30 or ORF54 into MeWo cells. 
 Initially, the sensitivity of untransfected MeWo cells to geneticin was determined.   
The geneticin sensitivity assay was used to find the LC75 concentration of untransfected 
MeWos (Figure 7).   
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Figure 7.  MeWo cells were diluted in 0.5 ml, 1 ml, and 2 ml with varying amounts of 
geneticin.  After adding geneticin, pictures were taken after 1 day (blue), 5 days (red), 
and 8 days (green).   
 
On day 13, the MeWos with 250 µg/ml and 500 µg/ml of geneticin had only dead 
cells whereas the other plates were confluent.  Based on Figure 7, the addition of 375 
µg/ml of geneticin to MeWo cells was chosen as LC75.   
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ORF30 and ORF54 were transfected with a DNA:Lipofectamine ratio of 4 µg 
DNA to 10 µl Lipofectamine.  Indirect immunofluorescence (method 1) of pORF30 and 
pORF54 at 6, 15, and 27 days post-transfection showed weak expression.  Protein 
expression was analyzed by immunoblotting of pORF54 and pORF30 MeWo cell lines 
one month post-transfection.  No bands were detected after the immunoblot procedure 
confirmed the IF results.  
 
CV-1 Flp-In Cell Line 
Due to low gene expression in MeWo cells, the Flp-In two-plasmid system 
(Invitrogen) was used to isolate isogenic cell lines expressing individual VZV ORFs.  
Note that even if a cell line expressed the protein of interest, complementation of an 
encapsidation mutant is dependent on whether the host cell line can support VZV 
replication.  Prior to proceeding with the Flp-In strategy, it was important to be sure that 
the CV-1 Flp-In cell line could support wild type VZV replication.  A plaque assay 
comparing MeWo and CV-1 from a 7-day infection resulted in plaques in MeWos and no 
visible plaques for CV-1 cells.  Next, VZV infection was evaluated by a more sensitive 
method, indirect immunofluorescence (method 2).  Ten days post-infection, fluorescence 
was readily observed using the anti-gE antibody in both MeWos and CV-1 cells.  
Infected MeWo cells were abundant and showed rounding typical of viral infection.  
Infected CV-1 cells showed sporadic plaque formation indicating that CV-1 could 
support VZV infection (Figure 8). 
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Figure 8.  Indirect immunofluorescence of 10-day VZV infection.  Relative field of CV-1 
(A) and MeWo (C) infected cells.  A close-up of CV-1 and MeWo infected cells is shown 
in panel (B) and (D) respectively.  VZV glycoprotein E staining appears green (FITC) 
and nuclei appear blue (DAPI).   
 
Next, it was important to confirm whether CV-1 cells could transiently express 
VZV genes.  CV-1 cells were transfected with Flp-In vectors (pcDNA pEF5/FRT/V5-D-
Topo) containing VZV ORF25, ORF30, or ORF54.  After 3 to 4 days post-transfection, 
indirect immunofluorescence (method 1) showed transient expression of ORF25, ORF54 
and ORF30 in CV-1 cells (Figure 9).   
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Figure 9.  Indirect immunofluorescence at 4 days post-transfection of (left to right) 
pORF25, pORF54, and pORF30 using a V5 tag primary antibody and Rhodamine Red 
secondary antibody.  VZV ORF proteins appear red and DAPI stained nuclei appear blue.   
 
Transfection optimization of CV-1 cells using Flp-In ORF30 vector was 
attempted to find optimal conditions for an ORF30 stable cell line.  The amounts of DNA 
(2 µg, 4 µg), Lipofectamine (10 µl, 20 µl), and hygromycin B (100 µg/ml, 200 µg/ml) 
were varied.  The literature suggested that 100 to 200 µg/ml of hygromycin B would be 
required to select for stable cell lines.  The 2 µg DNA wells contained 1.8 µg pOG44 and 
0.2 µg Flp-In ORF30 vector, while the 4 µg DNA wells contained 3.6 µg pOG44 and 0.4 
µg Flp-In ORF30 vector.  The negative control was pOG44 vector only (without Flp-In 
ORF30 vector).  The positive control was Flp-In vector only (without pOG44 vector).  
Incubation with DNA/Lipofectamine complex lasted 9 hours.  The wells with 20 µl of 
Lipofectamine did not have as many live cells as the 10 µl Lipofectamine wells 3 days 
post-transfection.  The transfected cells were split 1:4 into TC-100 plates to give an 11X 
dilution to allow the cells to grow.  Cells were placed in hygromycin B 3 days post 
transfection.   
Seventeen days post-transfection, the number of colonies per plate was 
enumerated to estimate the efficiency of transformation based on varying the parameters 
(Table 1).  At 22 days post-infection, the isolated colonies were picked and expanded into 
12-well plates for stable cell line isolation.  The concentration of hygromycin B during 
selection was changed from 200 µg/ml to 100 µg/ml to decrease the stress on the cells.  
Colonies that were not picked for expansion at this time were assayed for β-gal activity to 
see if any cells accepted the Flp-In ORF30 vector.  A lack of β-gal expression is an 
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indicator that the ORF construct “flipped” into the cell genome and disrupted expression 
of β-gal.  A mixture of both white and blue colonies was observed indicating that some 
CV-1 Flp-In cells accepted the Flp-In ORF30 vector (data not shown). 
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Table 1.  Transfection optimization for a stable Flp-In ORF30 cell line.  Colonies were 
enumerated at 17 days post-transfection.  
Number of Colonies Post-Transfection 
DNA Lipofectamine 2000 Hygromycin Replicate Number of Colonies 
2 µg 
10 µl 
100 µg/ml 
1 20+ 
2 50+ 
3 50+ 
20 µl 
1 20+ 
2 20 
3 5 
10 µl 
200 µg/ml 
1 0 
2 0 
3 5 
20 µl 
1 0 
2 0 
3 0 
4 µg 
10 µl 
100 µg/ml 
(+) TMTC 
2 30+ 
3 50+ 
20 µl 
1 3 
2 0 
3 1 
10 µl 
200 µg/ml 
1 1 
2 2 
3 0 
1.8 µg 
20 µl 
(-) 0 
4 µg 
2 0 
3 0 
(+) = Flp-In vector only 
(-) = pOG44 vector only 
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 Six isolated colonies survived the colony transfer from 6-wells into 12-wells and 
became a set of ORF30 cell lines to be expanded and assayed.  ORF30 cell lines were 
expanded into duplicate cultures and assayed for β-gal activity at 1 and 3 months after the 
original transfection.  Four of the cell lines stained white (no β-gal expression) and two 
stained white/blue.  The lack of expression in the four white lines suggested that each had 
been expanded and was a potential isogenic ORF30 cell line (Figure 10).   
 
 
Figure 10.  First β-gal assay of ORF30 cell lines after colony isolation.  Four white wells 
and 2 white/blue wells were compared to the untransfected CV-1 positive control (+).  
From left, an example of a white well, white/blue well, and blue well under the 
microscope.  
 
 The presence of the ORF30 gene in the resistant cell lines was tested by PCR.  
Sixty days after the original transfection, genomic DNA was extracted using the Multi-
Plex PCR kit.  Primers 69 and 70 were used to amplify ORF30 from genomic DNA.  A 
fragment of 770 bp was expected if the cells harbored the ORF30 gene.  A plasmid 
containing the cloned wild-type ORF30 gene acted as the positive control (+).  The cell 
line samples yielded a fragment at a position comparable to the positive control (Figure 
11).  The intensity of the ORF30 bands suggested with some confidence that the ORF30 
gene was contained within the genomic DNA.  Unfortunately, repeat PCR of the same 
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samples using the same PCR conditions did not yield positive results.  A second lot of 
genomic DNA was prepared and re-assayed by PCR.  Unfortunately, only the positive 
control band showed up.  This variability was a concern, in particular because 
contamination could not be ruled out as a source of the positive results in the first PCR 
assay (Figure 11).   
 
 
Figure 11.  PCR amplified from ORF30 cell lines.  From left, positive control for ORF30 
compared to 770 bp fragments isolated from genomic DNA from 6 ORF30 cell lines.   
 
Therefore, a third genomic extraction of the ORF30 cell lines was performed 
using the Multi-Plex PCR kit.  This time, when the genomic DNA was checked for 
concentration and purity, the 260/280 absorbance ratio ranged from 0.59 to 0.68 
indicating protein contamination.  Subsequently, the Qiagen Blood and Cell Culture 
DNA Mini kit was used to extract and purify genomic DNA from the ORF30 cell lines.  
Both the concentration and 260/280 ratio improved, the latter to a range of 1.86 to 2.05.  
Genomic DNA was analyzed on a 0.8% agarose gel before running PCR reactions.  
Varying the PCR parameters, extracting DNA from TC-100 plates instead of 6-well 
plates, and reducing the potential for contamination (new water, DNA loading dye, and 
primer stock) led to a potential confirmation of the ORF30 gene’s presence in the cell 
lines (Figure 12).   
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Figure 12.  PCR amplified from ORF30 cell lines after genomic DNA extraction from 
cell lysates.  From the left lane, 1 Kb ladder, 770 bp positive control (+), and PCR 
fragments from ORF30 cell lines corresponding to positive control band.     
 
 It was important to confirm ORF30 protein expression in any potential 
complementing cell line.  At 50 days post-transfection, immunoblot analysis was 
performed with an anti-V5 antibody that should recognize a V5 expressed epitope tag on 
the ORF30 protein.  Cell lysates were tested three times with two different types of V5 
antibodies (mouse and goat), but no band representative of pORF30 (92.1 kDa) could be 
detected.   
It was possible that VZV ORF30 protein expression was too low to detect without 
first concentrating the ORF30 protein before immunoblotting.  At 80 days post-
transfection, the Pierce Classic IP Kit (method 1) was used to extract pORF30 from cell 
lysates by antibody-protein complex bound to agarose beads.  Again, immunoblotting of 
the immunoprecipitated material did not reveal any bands of the expected size.   
 Additionally, indirect immunofluorescence (method 1) performed at 100 days 
post-transfection showed that ORF30 cell lines (Figure 13C) looked similar to 
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untransfected CV-1 cells (negative control) (Figure 13A).  Almost one year post-
transfection, similar results were observed (Figure 14).  ORF30 cell lines (Figure 14C) 
looked similar to untransfected CV-1 cells (negative control) (Figure 14A). 
 
 
Figure 13.  Indirect immunofluorescence of 100 days post-transfection of untransfected 
CV-1 cells as negative control (A), pORF25 cell line (B), pORF30 cell line (C), and 
pORF54 cell line (D) with FITC secondary antibody.   
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Figure 14.  Indirect immunofluorescence of (A) untransfected CV-1 cells, (B) 48 hours 
post-transfection using Flp-In ORF54 vector, (C) year-old ORF30 cell line, and (D) 8 
month-old ORF54 cell line using FITC secondary antibody.   
 
 The lack of protein expression was perplexing.  Complementation of an ORF30 
cell line with ΔORF30 BAC VZV Maxi DNA would probably be the most sensitive and 
certainly the most valuable test for determining if the cell line is expressing the protein, 
regardless of protein expression level, and thus capable of supporting mutant replication.  
Seven days post-transfection, it was difficult, yet possible, to find GFP expressing CV-1 
cells from the ΔORF30 BAC virus.  There were only single cells expressing GFP and no 
obvious clusters of GFP cells (Figure 15).  Successful complementation of ΔORF30 BAC 
and ORF30 cell lines would have showed infection-like plaque formation and cell-to-cell 
spread.   
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Figure 15.  Seven day post-transfection of ΔORF30 BAC with untransfected Flp-In cell 
line (-) and ORF30 transfected cell line.  There were single GFP expressing cells in both 
(-) negative control and ORF30 cell line.   
 
Transfection of Flp-In ORF54 and ORF25 vectors into CV-1 cells was based on 
the experiments performed with ORF30.  Four days post-transfection, cells were diluted 
11X with varying concentrations of hygromycin B (0 µg/ml, 50 µg/ml, 100 µg/ml, 200 
µg/ml, and 400 µg/ml).  After 1 month of maintaining transfected CV-1 cells with the 
appropriate amount of hygromycin B, the cell lines to be further assayed were an ORF25 
cell line expanded in 100 µg/ml and an ORF54 cell line expanded in 200 µg/ml of 
hygromycin, respectively.  The ORF25 and ORF54 colonies were assayed for β-gal 
activity to see if any cells accepted the Flp-In vector. 
 Only white colonies were observed in the β-gal assay suggesting that the CV-1 
cells accepted the Flp-In vectors (Figure 16).  However, it was noted 7 months later that 
the ORF54 cell line contained a mixture of blue and white cells.  This is understandable 
since the ORF54 cell line was the only cell line with combined isolated colonies. 
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Figure 16.  β-gal assay one month post-transfection of ORF25 cell line selected at 100 
µg/ml hygromycin B, ORF54 cell line selected at 200 µg/ml hygromycin B, and 
untransfected CV-1 cells as negative control.  
 
 One month post transfection, ORF25 and ORF54 cell lines were analyzed by 
immunoblotting for protein expression.  There appeared to be a small band detected in 
the ORF25 lysate (Figure 17).  The molecular mass of pORF25 containing the V5 tag is 
predicted to be approximately 22.6 kDa and hence, the band observed on the blot would 
be too small to represent full-length pORF25.  No band of the predicted molecular mass 
for pORF54-V5 and pORF30-V5 was observed (91 kDa and 92 kDa, respectively).  In 
addition, immunoprecipitation (method 2) followed by an immunoblot resulted in no 
bands representative of pORF54 (data not shown).   
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Figure 17.  Immunoblot using V5 primary antibody for one month post-transfection of 
ORF30, ORF25, and ORF54 cell lines.  From left, ladder, untransfected Flp-In cells (-), 
untransfected Flp-In cells (-), ORF30 cell lines, ORF25 cell lines selected at 0, 50, 100, 
100 µg/ml hygromycin B, and ORF54 cell lines selected at 50 and 100 µg/ml 
hygromycin.  Band in ORF25 at 100 µg/ml hygromycin was exposed for 1 minute.   
 
 Three months post-transfection, an indirect immunofluorescence (method 1) assay 
showed that the untransfected CV-1 cells (negative control; Figure14A) looked similar to 
the ORF54 (Figure 13D) and ORF25 (Figure 13B) transfected CV-1 cells.  Eight months 
post-transfection, another indirect immunofluorescence (method 2) assay showed only 
background staining similar to untransfected CV-1 cells in comparison to ORF54 cell line 
(Figure 14D).    
 The presence of the ORF25 and ORF54 genes in each cell line was assayed by 
PCR.  After using the Multi-Plex PCR kit for genomic DNA extraction, no genomic 
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DNA appeared on a 0.8% agarose gel.  The Qiagen Genomic DNA Extraction and 
Purification kit resulted in higher concentrations and purity.  Multiple attempts at PCR 
were performed and included adjusting many parameters: annealing temperature, 
extension times, quantity of DNA, concentration of magnesium, primer sets, and different 
polymerases (Phusion versus Taq).  It was not possible to confirm the presence of either 
ORF25 or ORF54 in their respective Flp-In lines (Figure 18).   
 
 
Figure 18.  PCR products on 0.8% agarose gel.  Gel on left:  1 Kb ladder, double negative 
control (no DNA), positive control pcDNA-ORF25, ORF25 cell line.  Gel on right:  
lambda HindIII ladder, double negative control, negative control (untransfected CV-1), 
positive control pcDNA-ORF54, ORF54 cell line, 1 Kb ladder.   
 
Similar to the ORF30 cell line, results were mixed.  Some assays suggested that 
the cell lines were positive while others did not confirm the results.  ΔORF30 BAC DNA 
and ΔORF54 BAC DNA are new reagents that became available to test for 
complementation of ORF30 and ORF54 cell lines regardless of the prior results.  
ΔORF54 BAC DNA and ΔORF30 BAC DNA was transfected into the ORF54 and 
ORF30 Flp-In cell line respectively.  Seven days post-transfection, GFP expression was 
observed in the ORF54 cell line from the ΔORF54 BAC virus.  There were single cells 
expressing GFP (Figure 19D) and some larger clusters of GFP-expressing cells (potential 
plaque formation; Figure 19C) suggesting that the mutant ORF54 genome was 
complemented.   
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Figure 19.  GFP-expressing CV-1 cells from ΔORF BAC DNA seven days post-
transfection of (A) CV-1 cells with ΔORF30 BAC DNA, (B) CV-1 cells with ΔORF54 
BAC DNA, and (C & D) ORF54 cell line complemented with ΔORF54 BAC DNA. 
 
Discussion 
 Were there any VZV ORF expressing cell lines isolated?  Multiple assays were 
used to assess this:  indirect immunofluorescence, β-gal assay, immunoblot, 
immunoprecipitation followed by immunoblot, PCR, and complementation of ΔORF 
BAC DNA.  In all cases, mixed results were obtained.  Cells lines were clearly resistant 
to hygromycin B and had the correct β-gal phenotype.  However, protein expression 
could never be confirmed directly.  This could be due to suppression of gene expression, 
very low levels of gene expression, or low levels of protein expression.   
Originally, MeWo cells were selected for the production of stable cell lines since 
VZV was known to replicate in these cells efficiently.  Additionally, our laboratory had 
already shown that the encapsidation proteins could be expressed by transient 
transfection in these cells (Visalli et al., 2007).  However, isolating a stable MeWo cell 
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line proved difficult.  Even at ten days post-transfection no florescence was detected.  It 
was decided to try using an alternative cell line that was specifically designed for the 
isolation of isogenic, stable cell lines.   
 The Flp-In system was designed for isogenic, stable cell line production.  The 
Flp-In vector had reporter genes to indicate successful ORF integration into one site of 
the host cell genome.  The purpose of the pOG44 vector was to facilitate integration of 
the Flp-In vector.  However, successful integration was dependent on co-transfection of 
the Flp-In pOG44 vectors into the same cell.  The β-gal assay produced consistent results 
in that “white” non-β-gal expression cell lines were isolated for all three VZV ORFs 
attempted.  A negative β-gal assay meant the VZV ORF should have integrated 
successfully into the host’s genome.  Confirmation of the presence of the gene in the 
various cell lines was mixed with some positive PCR results for the ORF30 cell line, but 
not for the ORF54 and ORF25 cell lines.  
 Transient transfection was successful for VZV protein expression based on 
immunofluorescence; however, after a few months the cell lines appeared comparable to 
untransfected cells based on indirect immunofluorescence or immunoblot.  During 
transient transfection, the human elongation factor 1α promoter driving the cloned VZV 
gene was probably expressed in the cytoplasm.  However, after passages, the host will 
degrade unincorporated plasmid DNA.  For stable cell lines, the ORF must be 
incorporated into the host’s genome.   
 There are a number of reasons that the cells lines may not have expressed 
detectable protein.  The human elongation factor 1α has been shown to have high 
constitutive expression, but expression depends on each cell line (Qin et al., 2010).  In 
certain cell lines, the promoters can be silenced by methylation (Brooks et al., 2004).  
Although the reporter genes, hygromycin and lacZ-Zeocin, suggested positive ORF 
integration into the host cell line, this did not guarantee expression of the VZV ORF;i.e., 
the reporter genes are expressed via a separate promoter from the VZV ORF.  Even 
though the Flp-In system is designed for production of stable cell lines, ORF 
recombination and integration into the genome is a rare event.  Perhaps additional 
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transfections and isolation of more individual colonies would have yielded a stable cell 
line with all of the desired genotypes and phenotypes.   
 Constitutive expression of the viral protein could lead to cellular toxicity.  It is 
possible that constitutive VZV pORF expression is too toxic for the CV-1 cells and 
therefore selection of a stable cell line expressing detectable encapsidation protein is 
impossible.  Instead of using the human elongation factor 1α as a promoter, an inducible 
promoter would be interesting to try if constitutive VZV ORF expression proved to be 
toxic.   
 Even though the VZV ORFs were cloned directionally into the plasmids and the 
Flp-In system is designed for targeted, directional recombination, perhaps the lack of 
protein expression was due to improper ORF orientation.  Using ORF and lacZ-Zeocin 
primers for PCR might confirm the ORF’s orientation and location in the host cell 
genome.  
 Part way through the project, ΔORF VZV BAC genomes with individual 
mutations in the encapsidation genes became available from an outside lab.  
Complementation of a specific mutant genome with its respective cell line should result 
in VZV replication.  This would have been the best way of selecting cell lines by first 
expanding colonies, then transfecting colonies with ΔORF VZV BAC.  Duplicate 
colonies would first have to be isolated before testing each colony for complementation.  
If infection occurred, complementation was successful since VZV cannot replicate 
without the encapsidation proteins. 
 The overall goal of the project was to isolate encapsidation gene-expressing cell 
lines so that encapsidation mutants could be grown up in large quantities and studied in 
cell culture.  The mutants could be used to prove that each encapsidation protein is 
essential for VZV encapsidation.  For example, would empty capsids and un-cleaved 
DNA accumulate in the nucleus?  Which encapsidation mutant virus is deficient in DNA 
cleavage versus DNA translocation?  These would be valuable tools in further dissecting 
viral DNA encapsidation in large mammalian DNA viruses. 
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CHAPTER 2 
 
 
STRATEGY 2: PREPARATION OF AN ORF54 TRANSPOSON LIBRARY TO USE  
 
WITH A Δ54 BACTERIAL ARTIFICIAL CHROMOSOME MUTANT AS A TOOL  
 
TO STUDY PORTAL FUNCTION 
 
 
 
Introduction 
Portal proteins of HSV-1 (Trus et al., 2004), HCMV (Dittmer & Bogner, 2005), 
and recently VZV (Howard et al., 2012) have been isolated; however, little is known 
about the role of specific functional regions within the portal polypeptides.  The 2307 bp 
VZV ORF54 gene encodes a 769 amino acid polypeptide.  It is hypothesized that specific 
regions of pORF54 will be essential for interaction with the viral capsid and terminase 
proteins, and for translocation of viral DNA.   
An ORF54 transposon library was prepared for use in functional studies of 
pORF54.  Once the transposons are removed, ORF54 proteins with19 amino acid in-
frame insertions throughout the ORF54 gene will be available for study.  The importance 
of different regions of pORF54 for the production of infectious virus can then be 
characterized by attempting to complement an ORF54 null virus (ΔORF54 VZV BAC) 
with the mutated ORF54 genes encoding the insertions.  
The Epicentre EZ-Tn5 In-Frame Linker Insertion Kit (Epicentre, Madison, WI) 
was used to randomly mutate an ORF54 plasmid and generate a saturated transposon 
library (Figure 20).  This will ultimately be used to isolate a library of plasmids 
containing insertions that result in 19 amino acid in-frame insertions within ORF54 
(Figure 21).  Plasmid DNA will be isolated from individual E. coli transformants and 
sequenced to identify the location of each insertion.
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Methods 
 
DNA Extraction 
 ORF54 pCR4Blunt-TOPO (Invitrogen) DNA was extracted and purified from E. 
coli using a Qiagen miniprep kit.   
 
DNA Digests 
 Restriction enzymes were used following the manufacture’s recommendations 
with slight modifications:  EcoR1 (FastDigest), Not1 (Promega), Sty1 (New England 
BioLabs), and Sap1 (New England BioLabs).  
 
PCR 
 To allow for recombination into the ΔORF54 BAC DNA, a DNA fragment 
containing ORF54 with additional 5’ and 3’ flanking VZV DNA was isolated from 
genomic VZV Ellen strain by PCR.  The primers encompassing the entire ORF54 gene 
and parts of the ORF53 and ORF55 genes were named VTFlank primers.  The following 
conditions were successfully used to generate a PCR product of the expected size.  
 
VTFlank primers: 
Forward:  5’-GCG AAT TCA AGG TCC TAT TTG ACA CT-3’ 
Reverse:  5’-TCA CCC GGG ATT GTG TTT ATC GGA-3’ 
 
PCR:
0.5 µl VZV Ellen strain 
1 µl forward primer 
1 µl reverse primer 
4 µl HF buffer 
0.4 µl dNTP 
0.2 µl phusion polymerase 
12.9 µl water 
Initial denature:  98°C, 3 min 
Denature:  98°C, 10s 
Anneal:  52°C, 30 s 
Extension:  72°C, 1 min 
Final extension:  72°C, 5 min 
Total cycles:  35
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Cloning and Transformation 
 Following PCR, DNA was purified via electrophoresis on a 0.8% agarose gel 
using the Qiagen QIAquick Gel Extraction kit.  The PCR product was cloned into the 
pCR4Blunt-TOPO vector (Invitrogen, Cat. K2875-J10) and transformed into E. coli.  For 
the cloning reaction, 4 µl of PCR fragment, 1 µl salt solution, and 1 µl vector was used.  
Cloning is highly efficient since insertion of the desired fragment into the vector disrupts 
the lethal ccdB E. coli gene and only E. coli with the insert will grow.  Transformed E. 
coli were incubated at 37oC and selected on LB plates containing kanamycin (50 µg/ml).  
Colonies were selected and incubated in LB media at 37°C.  Plasmid DNA was prepared 
and screened for the desired PCR product by EcoR1 digestion.   
 
DNA Terminator End Repair Kit 
 DNA digested with NotI was incubated with 20 µl of DNA purified from an 
agarose gel.  The reaction mixture of 20 µl DNA, 18 µl water, 10 µl buffer, and 2 µl of 
Terminator enzyme was incubated for 30 minutes at room temperature. Treated DNA 
was purified by running a 0.8% agarose gel.  Bands were extracted with the GET 
Agarose DNA kit (G BioSciences) into 20 µl water.   
 
Ligation 
 The T4 ligation (Promega) reaction mixture consisted of 20 µl of extracted DNA 
in water, 2.5 µl of 10X ligase buffer, and 2.5 µl T4 DNA ligase.  The components were 
mixed gently and incubated overnight at 4°C.   
 
 
 
 
 
 
 
 
 40 
Mutagenesis 
 The EZ-Tn5 In-Frame Linker Insertion Kit (Epicentre) was used to generate the 
ORF54 transposon library in E. coli (Figure 20).  The following reactions were prepared
ORF54 vector 
1 µl 10X buffer 
1.25 µl DNA (159 ng/µl) 
0.4 µl transposon 
6.35 µl water 
1 µl transposase 
pUC19 vector 
1 µl 10X buffer 
2 µl DNA 
0.5 µl transposon 
5.5 µl water 
1 µl transposase 
 The mutagenesis reactions were incubated for 2 hours at 37°C and stored at -
20°C.  One microliter of the mutagenesis reaction was used to transform Lucigen HI-
Control 10G SOLOS competent E. coli.  Transformed E. coli were spread on kanamycin 
plates (50 µg/ml) at 10 µl, 20 µl, 30 µl, 40 µl, and 50 µl.  After 24 hours of incubation at 
37oC, 10 colonies were selected and grown at 37°C overnight in LB media containing 50 
µg/ml kanamycin.  Miniprepped DNA was digested with Not1 to confirm the presence of 
a transposon, to remove the transposon, and to roughly determine the location of the 
transposon insertion (Figure 21).  
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Figure 20.  General procedure for transposon mutagenesis. 
http://www.epibio.com/item.asp?id=289. 
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Figure 21.  After removing the transposon by Not1 digestion, ligating sticky ends makes 
an insertion in the plasmid.  http://www.epibio.com/item.asp?id=289. 
 
Results 
 To use the Epicentre EZ-Tn5 In-Frame Linker Insertion Kit, the Not1 site on the 
pCR4Blunt-TOPO (Figure 22) had to be removed because transposon removal after 
mutagenesis is dependent on Not1 digestion (Figure 21).  The TOPO vector was digested 
with Not1, purified by electrophoresis on a 0.8% agarose gel, extracted from the gel, and 
repaired by using the DNA Terminator End Repair Kit (Middleton, WI) to make the Not1 
sticky ends to blunt ends.  The treated, linear vector was re-purified by gel extraction and 
re-circularized using T4 DNA Ligase.  The ligation product was transformed into E. coli.  
To identify E. coli containing pCR4Blunt-TOPO without the Not1 site, plasmid DNA 
was isolated and digested with Not1 and compared to Not1 treated or untreated vector on 
an agarose gel.  If the Not1 site was deleted, digested plasmid DNA appeared similar to 
the undigested vector, i.e.uncut.   
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Figure 22.  Vector used for ORF54 insertion, Not1 deletion, and kanamycin gene 
disruption for the development of the foundation for the ORF54 transposon library.  
http://tools.invitrogen.com/content/sfs/vectors/pcr4blunttopo_map.pdf. 
 
 Additionally, to use the transposon mutagenesis kit, the kanamycin resistant gene 
in the pCR4Blunt-TOPO (Figure 22) had to be deleted because screening for successful 
transposon insertion is dependent on kanamycin selection (Figure 21).  There were two 
Sty1 restriction enzyme sites within the kanamycin gene.  When the plasmid was digested 
with Sty1, 623 base pairs of the kanamycin gene were removed.  After digestion, the 
linearized vector was run on an agarose gel; the appropriate band was extracted and re-
circularized via ligase.  The ligation product was transformed into E. coli and colonies 
were selected with ampicillin.  At this point, all colonies grew whether kanamycin was 
disrupted or not.  Therefore, colonies were tested for sensitivity to kanamycin and 
digested with Sap1 for deletion confirmation.  Colonies that did not grow in the presence 
of kanamycin contained the final construct to be used as the ORF54 control plasmid to 
complement the ΔORF54 VZV BAC after co-transfection and as the foundation for 
construction of the transposon library.  
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 The ORF54 gene with flanking regions was isolated from the VZV Ellen strain by 
PCR (Figure 23).  The VTFlank forward primer starts at nucleotide 93207 and the reverse 
primer ends at nucleotide 96372.  Therefore, the DNA fragment should be 3165 bp.   
 
 
Figure 23. ORF54 gene was isolated by PCR using VTFlank primers to obtain a 3165 bp 
fragment.  From left, HindIII ladder, negative control (no template DNA), positive 
control (+) with 75/76 primers from Ellen VZV strain, and ORF54 fragment from Ellen 
VZV strain.   
 
 After extracting the band, the DNA was cloned into pCR4Blunt-TOPO and 
transformed into E. coli (Figure 24).  Successful insertion of ORF54 into the vector was 
based on growth or no growth because the insertion disrupts the lethal ccdB E. coli gene.   
 
 
Figure 24.  Successful transformation of pCR4Blunt-TOPO vector into E. coli and 
insertion of ORF54 fragment vector. 
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 After growing transformed colonies and extracting DNA, the plasmid was 
digested with EcoR1 to confirm the presence of ORF54 insertion into the vector.  There 
are two EcoR1 sites flanking the ORF54 insert.  Successful insertion should give two 
bands with sizes of approximately 3165 bp and 3956 bp (Figure 25).  Samples #1 and #3 
were selected and transformed into E. coli to make stocks.   
 
 
Figure 25.  (A) Colonies from Figure 24 were digested with EcoR1 to confirm the 
presence of ORF54 vector in plasmid.  (B) Schematic of plasmid after successful ORF54 
insertion to show the 3165 bp and 3956 bp bands (not to scale). 
 
 Plasmid DNA from lanes #1 and #3 was linearized by Not1 digestion in order to 
delete the Not1 restriction site (Figure 26A).  Not1 digested fragments were first 
extracted from the gel then repaired from sticky ends generated by restriction enzyme 
digestion to blunt ends using the DNA Terminator End Repair kit (Figure 26B).  The 
DNA Termination reaction changed the 5’ and 3’ DNA ends so that a Not1 site will not 
be re-generated upon re-ligation.  Treated DNA was purified, extracted, and re-ligated. 
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Figure 26.  (A) Gel on left is plasmid DNA digested with Not1.  Bands were extracted 
then repaired by DNA Termination reaction.  (B) Gel on right is DNA after Termination 
reaction.  These bands were extracted, re-ligated, and transformed into E. coli (Figure 
27).   
 
 E. coli was transformed with varying amounts of ligated DNA (3 µl, 5 µl, 10 µl) 
from Figure 26B, and 2 µl of pcORF54 DNA (has Not1 site) served as positive control.  
E. coli was spread on LB plates containing kanamycin and incubated at 37oC (Figure 27). 
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Figure 27.  Transformation of ORF54 vector at varying amounts of DNA after Not1 
deletion process (Not1 digested, sticky ends repaired, ligated, and then transformed into 
E. coli).  
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 Eight colonies were selected from Figure 27 and plasmid DNA was prepared for 
Not1 digestion to distinguish between plasmids with or without Not1 site.  DNA was 
digested with Not1 and compared to undigested DNA.  Not1 digested DNA lanes that 
were similar to undigested lanes were candidates for plasmids lacking the native Not1 
site (Figure 28).   
 
 
Figure 28.  Lanes with asterisks are Not1 digested DNA whereas lanes without asterisks 
are undigested DNA.  Colonies #6 and #10 were sequenced to verify the deletion of Not1 
site since the digested DNA was similar to undigested DNA.   
 
 Samples #6 and #10 were sequenced to verify that the Not1 site was removed.  
The data from sequencing showed plasmid DNAs from #6 and #10 had no Not1 site 
(Figure 29).  Colony 10 was picked for the following experiments.   
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Figure 29.  Colonies #6 and #10 were sequenced to verify that Not1 site was disrupted.  
Yellow shows EcoR1 site undisrupted, green shows Not1 site, and red shows the 
sequence change.    
 
 Deletion of native kanamycin gene in the vector was necessary because selection 
for transposon insertion depends on kanamycin selection.  The ORF54 vector without 
Not1 was digested with Sty1 to remove 623 bp of the kanamycin gene.  The digest was 
expected to yield two bands of 623 bp and 6498 bp (Figure 30).   
 
 
Figure 30.  Kanamycin gene was disrupted by deleting 623 bp by Sty1 digestion.  Gel of 
left shows plasmid DNA after Sty1 digestion.  Diagram on right (not to scale) shows 
schematic of Sty1 sites on ORF54 vector to show the 623 bp and 6498 bp bands. 
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The 6498 bp band from Figure 30 was extracted, ligated, and transformed into 
Lucigen’s HI-Control 10G SOLOS competent E. coli.  Colonies were selected on LB 
plates containing ampicillin.  Twenty individual colonies were picked with a sterile 
toothpick and transferred to LB agar containing 50 µg/ml of kanamycin.  In addition, 
nine colonies were picked and inoculated into LB media with 50 µg/ml of kanamycin 
(Figure 31).  E. coli that could not grow in the presence of kanamycin were expected to 
be the ORF54 backbone vector without a Not1 site and with a mutated (not functional) 
kanamycin gene.   
 
 
Figure 31.  After removal of 623 bp of kanamycin gene by Sty1 digestion, the ORF54 
vector was ligated and transformed into E. coli (A).  Transformants were tested in 
kanamycin agar (B) and LB media (C).  Turbidity in LB media can be compared in the 
tubes with ampicillin versus kanamycin.   
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 Sap1 digestion on extracted DNA from colonies #7 and #14 in Figure 31 
confirmed deletion of the kanamycin gene (Figure 32).  Plasmids possessing an intact 
kanamycin gene were expected to have fragments of 210 bp, 2107 bp, and 4774 bp.  
Plasmids with the kanamycin deletion were expected to have fragments of 2107 bp and 
4361 bp.  Plasmid #14 was selected as the ORF54 (vector without Not1 and Kan) vector 
for the mutagenesis library foundation.   
 
 
 52 
 
Figure 32.  Incomplete Sap1 digestion (digested*) of ORF54 vector after Not1 and 
kanamycin deletion.  DNA with kanamycin had a 4.8 Kbp fragment whereas the DNA 
without kanamycin had a 4.3 Kbp fragment.  Diagram of vectors are not to scale. 
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 The Epicentre EZ-Tn5 In-Frame Linker Insertion Kit (Epicentre) was used to 
prepare a random transposon library in the ORF54 plasmid described in the previous 
section.  The transposon randomly inserts into plasmid DNA via the action of Tn5 
transposase.  Subsequent removal of the transposon by Not1 digestion will result in a 19 
amino acid in-frame insertion.   
 The ORF54 vector without a native Not1 site and kanamycin gene, was 
mutagenized via transposon insertion then transformed into E. coli.  Successful 
transposon insertion resulted in the growth of kanamycin resistant colonies on LB agar 
containing kanamycin (Figure 33).  
 
 
Figure 33.  E. coli transformants containing a transposon insertion into the ORF54 vector.   
 
Plasmid DNA containing transposon insertions from ten Kanr colonies from 
Figure 33 were isolated and digested with Not1 to remove the transposon.  The presence 
of transposon sequences was detected after Not1 digestion and analyzed on agarose gels 
(Figure 34).  The 6498 bp band was extracted, re-ligated, and re-transformed into E. coli.  
Plasmids containing the 54 bp insert encoding a 19 amino acid in-frame deletion (Figure 
21) within ORF54 will be used in the complementation transfection studies similar to 
those described in discussion.   
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Figure 34.  The ORF54 vector was digested with Not1 to remove the transposon after 
mutagenesis reaction.  The 6498 bp band was extracted, ligated, and transformed into E. 
coli.  The 1.2 Kb band is the transposon removed.    
 
Discussion 
The construction of the ORF54 pCR4Blunt-TOPO vector without a native Not1 
site and native kanamycin gene was an essential step for the preparation of an ORF54 
transposon mutant library.  However, isolating an insertion mutant has proven to be 
challenging since digestion of transposon containing plasmids with Not1 does not go to 
completion (undigested Not1 vector in Figure 34).  Regardless, this vector provides the 
tools required for studying functional regions of pORF54.   
Numerous technical issues have to be overcome before the insertion library is 
useful.  Complementation of ΔORF54 VZV BAC in ARPE-19 cells needs to be 
optimized before mapping essential and non-essential regions of pORF54.  Co-
transfection of mutant BAC DNA with purified, linearized ORF54 DNA depends on a 
cell accepting both DNAs and recombination of the ORF54 gene into the BAC genome 
within the same cell.  To get around this issue, it may be more efficient to perform the 
homologous recombination in E. coli before transfection in order to isolate the 
recombined BAC DNA.  Then the complemented BAC DNA can be transfected directly 
into ARPE-19 cells to eliminate the potential for concurrent co-transfection and 
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recombination in ARPE-19 cells – a rare event at best.  The BAC DNA is hosted in a 
strain of E. coli that is defective in λ prophage (Exo, Beta, and Gam is expressed from 
defective prophage).  This protects recombined DNA and upon activation, recombination 
can be transiently switched on by temperature.  This strain has a temperature-dependent 
repressor that controls prophage expression and recombination.  By vigorously shaking 
cultures at 42°C for 15 minutes, the expression of the repressor is turned off, thus making 
BAC modification possible within the E. coli (Yu et al., 2000).  Utilizing this strain 
would involve a new protocol for complementation.  E. coli can be prepared for 
recombination by shifting temperature, then electroporating linear ORF54 vector into the 
E. coli strain harboring the ΔORF54 VZV BAC.  However, there is currently no reporter 
gene for selection of ORF54 recombining into the ΔORF54 VZV BAC and thus, another 
hurdle to overcome.   
Once the system is refined, functional regions of pORF54 can be characterized by 
comparing the complementation phenotype of ΔORF54 VZV BAC with ORF54 versus 
various mutated ORF54s.  A map depicting essential and non-essential regions of 
pORF54 can be generated based on which ORF54 mutations are lethal, crippling, or yield 
infectious virus.  The work described in this chapter provides the foundation for such 
studies
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CONCLUSIONS 
 
 
 
Characterizing functional regions of the Varicella-zoster virus encapsidation 
proteins will ultimately reveal the mechanism(s) underlying the process of DNA cleavage 
and packaging.  The complementing cell lines and mutated ORF54 library will be useful 
tools to experimentally prove that the encapsidation proteins are essential for VZV 
replication.  Additionally, mutant viruses generated from such studies could yield single 
replication cycle strains superior to the current live attenuated Oka vaccine strain because 
no replication competent VZV would be latent in the nervous system for reactivation.   
Future experiments for the encapsidation gene-expressing cell lines include the 
development of an ARPE-19 Flp-In cell line by incorporating the FRT site and lacZ-
Zeocin gene.  Testing different promoters in the host cell line should be explored; 
particularly inducible promoters could limit cell toxicity and control gene expression.   
Future experiments with the ORF54 transposon library include the accumulation 
of ORF54 plasmids containing the 19 amino acid insertions throughout pORF54 without 
the transposon.  Finding an efficient strategy to recombine ORF54 into the null 54 BAC 
construct will be essential for functional studies.
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